Oryzon Genomics has announced another key addition to its Scientific Advisory Board (SAB) to reinforce its development capabilities for its epigenetic drug ORY-1001 in leukemia and solid tumors with the appointment of Dr. Lori A. Kunkel. Dr. Kunkel has more than two decades of experience in oncology and immunology drug development and commercialization.